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An important criterion in the selection of polymers as carriers for drug delivery is
their metabolic fate in the body or biodegradation. Researchers have strived to engineer
or discover polymeric materials. Practically limitless are combinations of these materials
to regulate the physical and chemical properties of drug delivery systems, such as their
permeability, environmental response, surface functionality, biodegradability, and biore-
cognition sites to produce »intelligent» drug delivery systems. Of these, chitosan has re-
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Chitosan has become a focus of major interest in recent
years due to its excellent biocompatibility, biodegradabi-
lity and non-toxicity. Although this material has already
been extensively investigated in the design of different
types of drug delivery systems, it is still little explored
for stomach specific drug delivery systems. The objecti-
ve of the present investigation was to explore the poten-
tial of low molecular mass chitosan (LMCH) as carrier for
a hydrodynamically balanced system (HBS) for sustained
delivery of water soluble drug ciprofloxacin hydrochlo-
ride (CP). Various formulations were prepared by physi-
cal blending of drug and polymer(s) in varying ratios fo-
llowed by encapsulation into hard gelatin capsules. All
the formulations remained buoyant in 0.1 mol L–1 HCl
(pH 1.2) throughout the experiment. Effect of addition of
xanthan gum (XG) or ethyl cellulose (EC) on drug relea-
se was also investigated. Zero order drug release was ob-
tained from the formulations containing LMCH alone or
in combination with XG, and in one instance also with
EC. Our results suggest that LMCH alone or in combina-
tion with XG is an excellent material for stomach specific
sustained delivery of CP from hydrodynamically balan-
ced single unit capsules.
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ceived a great deal of attention due to its biocompatibility and low toxicity (1). Chitosan
has been extensively investigated in the design of many different types of drug carriers
for various administration routes such as oral, buccal, nasal, transdermal, parenteral, va-
ginal, cervical, intrauterine and rectal as well as in slow-release floating or gastroreten-
tive drug delivery systems (2). Chitosan could be ideal for use in formulations intended
to release drugs slowly in the stomach, since the gel formation by cationic chitosan, is
pronounced at acidic pH levels, results in marked retardant effects on drug release (3).
In previous studies of pharmaceutical formulations, little attention has been paid to the
effect of molecular mass of chitosan. Yassin et al. (4) prepared an extended release ga-
stroretentive mutiparticulate delivery system for verapamil by its incorporation into hy-
drogel beads made of medium molecular mass chitosan. Prepared beads showed slow
release as well as excellent buoyancy. Most of the other studies were carried out using
commercially produced chitosan (5). Considering the fact that very little work has been
carried out to investigate the applicability of LMCH, the authors have decided to under-
take the present work, first to check the applicability of LMCH in the design of single-
-unit hydrodynamically balanced capsule formulations using CP as a model drug and
secondly, its role alone or in combination with other polymers in sustaining drug release
from the prepared system.
EXPERIMENTAL
Materials
Ciprofloxacin hydrochloride (CP) was obtained as a gift sample from Ranbaxy Re-
search Laboratories, India. Low molecular mass chitosan (LMCH) was procured from
Sigma Aldrich Brookfield viscosity 20.00 cps of 1 % in 1 % acetic acid, degree of deacety-
lation (DD) > 80 %, molecular mass = 150,000, as supplied by the manufacturer. Xanthan
gum (XG) and ethyl cellulose (EC) were procured from the Central Drug House, India.
All other chemicals used were of analytical grade.
Methods
Drug-excipient and excipient-excipient interaction studies. – Fourier transform infrared
spectroscopy (FTIR) and differential scanning calorimetry (DSC) were employed to study
drug-excipient and excipient-excipient interactions. FTIR spectra were recorded for LMCH,
XG, CP and their physical mixtures using a FTIR facility (Shimadju, 8400S, Japan). Sam-
ples were prepared in KBr disks (2 mg sample in 200 mg KBr). The scanning range was
400–4000 cm–1 and the resolution was 2 cm–1.
For DSC (Universal V4.5A TA instrument, New Castle, USA) studies, approximately
5-mg samples of LMCH, XG, CP and their physical mixtures were placed individually
on a standard aluminium pan and heated to 400 °C (at a rate of 10 °C min–1). Character-
istic peaks and heat of melting were recorded.
Stability of ciprofloxacin hydrochloride in HCl. – Stability of CP in 0.1 and 0.01 mol L–1
(pH 1.2 and pH 2.0, respectively) HCl was determined in order to ascertain whether the
drug would remain stable throughout the period of drug release. Briefly, the drug was
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dissolved in either 0.1 or 0.01 mol L–1 HCl. The temperature of the system was main-
tained at 37 ± 0.5 °C. One mL aliquot was withdrawn every hour and replenished with
fresh dissolution medium. The samples so withdrawn were suitably diluted and absor-
bances of the solutions were measured at 276 nm ultraviolet (spectrophotometer Shimad-
zu 1800).
Preparation of hydrodynamically balanced capsules. – Single-unit hydrodynamically bal-
anced capsule formulations, whose composition is shown in Table I, were prepared by
physically blending CP and LMCH alone or in combination with XG or EC in a dou-
ble-cone blender for 15 min, followed by encapsulation in colorless transparent hard gel-
atin capsules (6).
Determination of drug concentration in formulations. – Drug concentration in each for-
mulation was determined in triplicate by emptying each formulation separately as com-
pletely as possible into 0.1 mol L–1 HCl at 37 ± 0.5 °C, followed by stirring for one hour
at 500 rpm. The solution was filtered through a 0.45-mm membrane filter, diluted suit-
ably and absorbance of the resultant solution was measured at 276 nm.
In vitro buoyancy studies. – The prepared capsule formulations were immersed in
900 mL of 0.1 mol L–1 HCl in a USP paddle type apparatus (7) at 50 rpm. The time dur-
ing which the formulations remained buoyant was observed and was taken as the float-
ing time.
Viscosity measurements. – The purpose of viscosity measurement studies was to study
the effect of gelled polymeric matrix on CP release. Further, viscosity measurement stud-
ies are also useful to study the possibility of polyelectrolyte complex formation between
oppositely charged macromolecules in the solution state.
The viscosity of sols (drug-free) prepared in 0.1 mol L–1 HCl was determined at
37 ± 1 °C with a Brookfield cone and plate rheometer with cone angle 0.8° (DV-III ULTRA,
Brookfield Engineering Laboratories, USA) using spindle cp 40. Evaluations were con-
ducted in triplicate.
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Table I. Composition of HBS capsules containing ciprofloxacin hydrochloride (CP) with and without
release modifiers
Formulation code LMCH (mg) XG (mg) EC (mg) CP (mg)a
F1 100 116
F2 100 174
F3 100 10 116
F4 100 20 116
F5 100 30 116
F6 100 10 174
F7 50 50 116
F8 100 116
F9 100 50 174
a Concentration of CP in formulations range 47.2–61.3 %.
Drug release and drug release mechanism. – Based on the buoyancy studies, formula-
tions showing good floatation were subjected to in vitro release studies performed in 900
mL 0.1 mol L–1 HCl (pH 1.2, 37 ± 0.5 °C) using the USP 27 paddle type apparatus (7) at
50 rpm. At predetermined intervals, 1-mL aliquots were withdrawn and replenished
with an equal volume of fresh dissolution medium. Withdrawn samples were suitably
diluted with 0.1 mol L–1 HCl and analyzed at 276 nm. Experiments were preformed in
triplicate.
In order to describe the kinetics of CP release from hydrodynamically balanced cap-
sule formulations, various equations were used, such as the zero-order rate equation,
which describes the systems where the release rate is independent of the concentration
of the dissolved species. The first-order equation describes the release from systems whe-
re dissolution rate is dependent on the concentration of the dissolving species (8). In vi-
tro data were also fitted to Higuchi’s square root model (9) which describes the release
from systems where the solid drug is dispersed in an insoluble matrix and the rate of
drug release is related to the rate of drug diffusion. Release of a drug from an insoluble
matrix is the square root of a time-dependent process based on Fickian diffusion:
Qt = kH t1/2
were Qt is the amount of drug released in time t and kH is the release rate conatant for
the Higuchi model.
Under some experimental situations, the release mechanism deviates from Fick’s
equation, following an anomalous behavior (non-Fickian release). In these cases a more
generic equation can be used. Korsmeyer et al. (10) developed a simple, semi-empirical
model, relating exponentially the drug release to the elapsed time.
Mt/M= ktn
where Mt/M is the fraction of drug released at time t; k is a constant reflecting the de-
sign variables of the system and n, the release exponent, is a parameter that depends on
the release mechanism and is thus used to characterize it. If the n value is 0.5 or less, the
release mechanism follows Fickian diffusion, and values 0.5 < n < 1 for mass transfer fol-
low a non-Fickian model (anomalous transport). Drug release follows zero-order drug
release and case-II transport if the n value is 1. For the values of n higher than 1, the
mechanism of drug release is regarded as super case-II transport. This model is used to
analyze the release from pharmaceutical polymeric dosage forms when the release me-
chanism is not well known or when more than one type of release phenomena are in-
volved.
Statistical analysis
The differences in average data were compared by simple analysis of variance (one-
-way analysis of variance) or Student’s t test (SigmaPlot® 11).
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RESULTS AND DISCUSSION
Solid state interaction studies
FTIR characterization and thermal characterization
The FTIR spectra of LMCH (Fig. 1a) exhibited absorption band at 1628, 1380 and
1320 cm–1 due to amide I, II and III. Absorption bands at 3371 and 2924 cm–1 are due to
the hydroxyl stretch and C-H stretch. The FTIR spectra of XG showed major absorption
bands at 1620 and 1419 cm–1 due to asymmetric and symmetric vibrations of COO– in
pyruvate and glucuronate groups (Fig. 1b). The FTIR spectra of the physical mixture of
LMCH and XG (LMCH:XG 3.33:1, without CP) showed slight shifting in absorption
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(c) LMCH + XG
(e) LMCH + XG + CP






































































































































































































































































































































































































































Fig. 1. FTIR spectra of: a) LMCH, b) XG, c) LMCH + XG physical mixture, d) CP, e) LMCH + XG +
CP physical mixture and f) dried LMCH + XG matrix after 60 min gelation in 0.1 mol L–1 HCl.
bands; band at 1628 cm–1 in LMCH shifted to 1612 cm–1, which suggests a slight change
in the environment of C=O and amide I (Fig. 1c). The FTIR spectra of pure CP (Fig. 1d)
showed absorption bands at 3525, 3379, 3086, 3024 and 2923 cm–1 corresponding to O-H
stretch of the carboxylic group, N-H stretch, C-H stretch of the aromatic group and C-H
stretch of the CH2 group, respectively. Further, absorption bands at 1705 and 1620 cm–1
are characteristic of C=O stretch of carboxylic acid and ketone group. On the other hand,
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Fig. 2. DSC thermograms (heat flow endo
down) of: a) XG, b) LMCH, c) physical mixture
LMCH + XG, d) CP, e) physical mixture CP +
LMCH, f) physical mixture CP + LMCH + XG.
(I), (II) and (III): DSC thermograms of gelled and
dried LMCH+XG polymer matrices after 15, 30
and 60 min gelation in 0.1 mol L–1 HCl.
FTIR spectra of the physical mixture of CP, LMCH and XG (LMCH:XG ratio 3.33:1, with
CP) showed no interaction with the drug (Fig. 1e), as major peaks of CP were found intact
in the spectra.
DSC is used for determination of the melting point, changes in crystallinity and to
detect any possible interaction between the drug and carrier. DSC thermograms for the
polymers, drug and their physical mixtures are shown in Fig. 2.
The DSC thermogram of XG has two endothermic peaks (Fig. 2a): a broad endother-
mic peak at 107 °C may represent loss of water, whereas the weak peak at 299 °C could
be attributed to the melting of XG. The DSC thermogram of LMCH showed two endo-
thermic peaks (Fig. 2b): the peak at 149.5 °C represents the glass transition temperature
of LMCH, whereas the broad endothermic peak at 312 °C may be attributed to the very
slow melting of LMCH.
The DSC thermogram of a physical mixture (same ratio as that used in the formula-
tion F5, but without CP) of LMCH and XG (3.33:1) showed two exothermic peaks at 319
and 349 °C (Fig. 2c). These peaks could be attributed to the degradation of LMCH and
XG rather than to interaction between the polymers.
The DSC thermogram of CP showed two endothermic peaks at 163 and 333 °C at-
tributed to loss of water and melting of CP (Fig. 2d). The DSC thermogram of physical
mixture of CP and LMCH showed two endothermic peaks at 144 and 325 °C attributed
to the glass transition temperature of the polymer and melting of CP (Fig. 2e). Although
the melting endotherm of CP was slightly shifted to lower temperature, it should not be
considered as interaction. On the other hand, the DSC thermogram of the physical mix-
ture of CP, LMCH and XG (F5) showed two endotherms and one exotherm (Fig. 2f). The
first endothermic peak at 277 °C could be attributed to the melting of XG, whereas the
second endothermic peak at 310 °C could be due to the melting of CP. The exothermic
peak at 349 °C seems to be a superimposed one and could be attributed to degradation
of both CP and XG.
Liquid state interaction studies
LMCH has many amino groups in its structure ready to be protonated when ex-
posed to acidic fluids (generally HCl or acetic acid). Further, LMCH is also reported to
form a polyelectrolyte complex (PEC) with anionic compounds (11). Although the data
from solid state interaction studies did not reveal interaction between LMCH and XG,
there is a strong possibility that such interaction might occur when the formulation is
exposed to 0.1 mol L–1 HCl during dissolution studies. Therefore, it is highly desirable
to study the interaction LMCH and XG when the formulation is at various stages of gel
formation due to penetration of dissolution medium.
DSC thermograms of samples (LMCH:XG 3.33:1) taken after a period of 15 (begin-
ning of gel formation at the outer surface of polymer matrix), 30 (gel formation at the
outer surface) and 60 min (penetration of dissolution medium into the core of polymer
matrix) of exposure to dissolution medium were recorded. The DSC thermograms of sam-
ples taken at 15 and 30 min interval revealed only a single endotherm at 112 and 114 °C,
respectively (Figs. 2I and II), whereas thermogram of the sample taken at 60 min showed
two endotherms at 115 and cca 333 °C, respectively (Fig. 2III). The broad endotherm at
333 °C may be the indication of the polyelectrolyte complex formation. To further con-
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firm PEC formation, the 60 min sample (LMCH:XG 3.33:1) was subjected to FTIR analy-
sis. The FTIR spectrum of the above mentioned gelled sample (Fig. 1f) showed new
bands at 1742 and 1544 cm–1. The appearance of these bands in the spectrum of gelled
sample (LMCH:XG 3.33:1, 60 min) could be taken as an evidence of change in the envi-
ronment of the amine group of LMCH through its interaction with the carboxylate group
on XG.
Stability of ciprofloxacin hydrochloride in HCl
CP showed significant (p < 0.05) degradation at both pHs (pH 1.2 and 2.0) at all con-
centrations. Drug degradation was also found to be concentration dependent.
At concentration 1 mg mL–1, 2 % of the CP degraded after 12 hours at both pHs,
whereas it was 6 % at concentrations 2 and 3 mg mL–1. At pH 2.0, degradation was 2.5 %
(2 mg mL–1) and 4.5 % (3 mg mL–1) after 12 hours. During the dissolution studies, it was
observed that there was negligible degradation of CP from hydrodynamically balanced
capsule formulations at both pHs. This could be attributed to the entrapment of CP in
the gel network, which prevented the drug from direct contact with dissolution medium
and it was slowly released. As CP degradation from hydrodynamically balanced capsule
formulations was almost the same at both pHs, it was decided to carry out drug release
studies in 0.1 mol L–1 HCl (Table II).
In vitro buoyancy studies and in vitro drug release studies
For efficient buoyancy, polymer swelling is vital. Further, there must be a balance
between swelling and water uptake (12, 13). In our case, the swelling of LMCH resulted
in an increase in bulk volume. The air entrapped in swollen chitosan maintains the den-
sity lower than unity, which ultimately confers buoyancy to the dosage form.
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Drug remaining in the
gel matrix (%)a
F1 99.9 ± 1.4 88.9 ± 4.4 10.2 ± 1.0
F2 100.2 ± 1.8 99.8 ± 1.8 ND
F3 99.6 ± 1.7 91.3 ± 3.5 7.6 ± 0.8
F4 99.4 ± 1.6 80.8 ± 4.1 17.2 ± 1.1
F5 99.5 ± 1.3 76.7 ± 4.3 21.6 ± 0.9
F6 98.9 ± 1.4 96.1 ± 3.1 3.1 ± 0.3
F7 99.6 ± 1.3 97.7 ± 2.1 1.2 ± 0.1
F8 102.1 ± 1.3 100.3 ± 1.9 ND
F9 100.5 ± 1.4 99.8 ± 2.2 ND
a All determinations were carried out in triplicate, mean ± SD.
ND – not detected
It was observed from the in vitro buoyancy studies that single-unit hydrodynami-
cally balanced capsule formulations containing LMCH alone (F1 and F2) or in combina-
tion with XG (F3, F4, F5 and F6) and EC (F7 and F9) and in one instance EC alone (F8)
exhibited immediate buoyancy when placed in 0.1 mol L–1 HCl with floatation time ran-
ged from 3–12 hours (Table III).
Fig. 3 illustrates the release profile of CP-loaded hydrodynamically balanced cap-
sule formulations. No lag time was observed in any of the formulations studied. The in
vitro release studies carried out in triplicate in 0.1 mol L–1 HCl revealed that, with the ex-
ception of F7 where about 90 % CP was released at the end of the first hour, all formula-
tions remained buoyant and capable of sustaining the drug release from hydrodynami-
cally balanced capsule formulations even though the solubility of CP in dissolution me-
dium was very high. Formulation F1 released CP slowly in 0.1 mol L–1 HCl. About 6 %
CP was released one hour after exposure to the dissolution medium and about 90 % CP
245
A. Verma et al.: Low molecular mass chitosan as carrier for a hydrodynamically balanced system for sustained delivery of
ciprofloxacin hydrochloride, Acta Pharm. 62 (2012) 237–250.
Table III. In vitro floating characteristics of HBS formulations
Formulation code Floatation time (h)
F1 remained floating for more than 12 h
F2 8
F3 remained floating for more than 12 h
F4 remained floating for more than 12 h
F5 remained floating for more than 12 h
F6 9
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Fig. 3. % Cumulative drug release profiles (mean ± SD, n = 3) from various formulations.
was released from the formulation by the end of the twelfth hour. With increase in CP
loading (F2), it was expected that the matrix of the gel formed would become more re-
laxed allowing easy solvent penetration leading to enhanced drug diffusion but the re-
lease profiles were virtually identical despite the change in CP loading.
It was observed that the disruption of capsule shell began as soon as it was placed
in dissolution medium but its complete disruption occurred in about 15 min. During
this period, the CP release was found to be negligible (< 0.1 %) but as the dissolution
medium penetrated through the disrupted capsule shell, the outer layer of polymer ma-
trix hydrated to form the gel and CP began to diffuse out of the polymer matrix. As the
time progressed, the dissolution medium penetrated deep into the matrix and the CP re-
lease was accelerated (from 15 % F1; from 21 % F2, after the second hour) from the matrix.
In formulation F7, EC was added as a buoyancy imparting agent because of its very
low bulk density and hydrophobic nature. Without EC, the formulation sank within 15
min. However, formulation F7 could not float for more than three hours. The poor buoy-
ancy could be attributed to the weak gel network formed by the low concentration of
LMCH in the formulation that could not hold EC particles in the gel network.
Drug concentration uniformity
The drug concentration uniformity (Table II) of various hydrodynamically balanced
capsule formulations for CP varied between 98.9 and 102.1 %. It could be attributed to
the little difference between drug densities [bulk density after 50 taps (V50) = 0.37 g cm–3]
and polymer [bulk density (V50): LMCH = 0.32 g cm–3, XG = 0.53 g cm–3, EC = 0.33 g
cm–3], selected drug/polymer (s) ratios, mixing efficiency time.
Effect of release modifiers
In order to determine the effect of incorporation of a hydrophilic or hydrophobic
polymer on drug release, a hydrocolloid like XG and a water insoluble cellulose deriva-
tive, EC, were selected. In case of formulations F3, F4 and F5 (Table I), a progressive
amount of XG (10, 20 and 30 %, m/m, of LMCH) was intimately blended with LMCH
and CP. The reason for incorporating XG into hydrodynamically balanced capsule for-
mulations was based on the fact that when the encapsulated LMCH-XG matrix contain-
ing CP was exposed to dissolution media, imbibition of the dissolution medium into it
initiated the formation of a gel layer around the polymer matrix. Now the diffusion of
dissolved drug through this gel layer was the determining factor in the improvement of
the dissolution rate. It has been reported that increased viscosity results in a correspond-
ing decrease in the drug release rate (14). Therefore, significant retardation of CP release
from these HBS formulations was presumed. However, unexpectedly, release of CP from
formulations F3 and F4 was not significantly different from that of formulation F1.
About 8 and 6 % CP, respectively, had been released at the end of the first hour and up
to 90 % CP was released from both formulations (F3 and F4) by the end of the twelfth
hour. The release profiles (F3 and F4) were virtually identical to formulation F1. In case
of formulations F3 and F4, it seems that the increase in viscosity of formulations (gel for-
mation during dissolution) was not sufficient to bring about a significant decrease in CP
release from the gelled matrix. On the other hand, a significant difference (p < 0.05) in
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CP release was observed between formulation F5 (gel layer remained floating in dissolu-
tion medium even after 12 hours) and F1. About 3 and 76 % CP had been released from
formulation F5 at the end of the first and twelfth hour, respectively. One of the reasons
for the decreased drug release rate from formulation F5 could be attributed to the in-
creased viscosity of the gelled polymeric system. For this purpose, we carried out vis-
cosity measurement studies to study the effect of the gelled polymeric matrix on CP re-
lease. It was observed that when solutions of LMCH and XG in 0.1 mol L–1 HCl were
mixed, the final solution containing 1 % (m/V) LMCH and 0.3 % (m/V) XG became sli-
ghtly hazy with evidence of precipitation and therefore its viscosity could not be mea-
sured accurately. This change in the appearance of the solution could be attributed to the
polyelectrolyte complex (PEC) formation between LMCH and XG, which was further sup-
ported by liquid state interaction studies. Charge interaction between cationic LMCH in
acidic medium and anionic XG (LMCH:XG ratio 3.33:1) resulted in the formation of
PEC, which resulted in strong gel formation capable of sustained release of CP. In case of
formulation F6, our experimental results indicated that the addition of XG could not
compensate for high CP concentration as about 13 and 96 % CP was released at the end
of the first and ninth hour resp., from formulation F6. This was not significantly differ-
ent from F2 (9 and 99 % CP at the end of the first and eighth hour). This could be attri-
buted to the formation of a comparatively relaxed gel matrix, which allowed easy sol-
vent penetration, leading to enhanced drug diffusion.
In formulation F7, the polymer matrix was composed of equal amounts of LMCH
and EC (50 %, m/m, each). The CP release from formulation F7 was found to be very fast
with about 90 % CP released at the end of the first hour and almost all the CP released at
the end of three hours. The possible reason for this burst release of the drug could be at-
tributed to the low concentration of LMCH that could not form a strong gel network.
In formulation F8, LMCH was completely replaced with EC. The CP release from
formulation F8 was significantly retarded compared to F7 with approximately 44 % of
CP released within the first hour and the entire drug was released in eight hours (F8 was
significantly different from F7, p = 0.05). The explanation could be that, because of large
differences in density between CP and EC, the CP seemed to be coated on the low den-
sity EC particles. When the formulation was exposed to the dissolution medium, it acted
as a raft and only the CP present on the exposed surface went into the dissolution me-
dium. Further release of CP from the polymer matrix was delayed due to poor penetra-
tion of dissolution medium into hydrophobic polymer matrix and thus retarded CP re-
lease from the formulation.
In formulation F9, the purpose of incorporating EC was to modify the hydrophili-
city of the polymer matrix. Drug release from formulation F9 was significantly sustained
compared to formulation F2 (p < 0.05) and F6 (p = 0.0008). About 15 % CP was released
by the end of the first hour, and almost all the CP had been released by the end of the
eleventh hour. Addition of EC to formulation F9 confered a certain degree of hydropho-
bicity to the formulation, which resulted in a significant retardation of drug release.
Mechanism of drug release
The in vitro release pattern of various formulations was analyzed by fitting the dis-
solution data into various kinetic models (Table IV). It was observed that for formula-
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tions F1, F2, F3, F4, F5 and F9, the R2 values were higher when fitted to a zero-order
equation, which indicated a zero-order release from these formulations. Formulations F6
and F8 followed the Higuchi release pattern, whereas formulation F7 followed first-or-
der release.
Drug diffusion through most types of polymeric systems is often best described by
Fickian diffusion, but in addition to diffusion, other processes are also important. There
is also relaxation of polymer chains that influences the drug release mechanisms (non-
-Fickian or anomalous diffusion). Release from initially dry, hydrophilic glassy polymers,
which swell when added to water and become rubbery, shows anomalous diffusion as a
result of the arrangement of macromolecular chains. The thermodynamic state of the po-
lymer and the penetrant concentration are responsible for the different types of diffu-
sion. A third class of diffusion is the case II diffusion (n = 1 for zero order) which is a
special case of non-Fickian diffusion. For the values of n higher than 1, the mechanism of
drug release is regarded as super case-II transport. Regarding the n values calculated for
the studied formulations, in most cases (F4, F5, F6, F8 and F9) a non-Fickian mechanism
was found to be predominant, which indicated that the CP release was dependent on its
solubility in the dissolution medium and swelling and erosion of the polymer matrix.
Formulation F7 followed the Fickian release pattern, which suggested that the govern-
ing factor for drug transport in the gels was ordinary diffusion. Formulation F1 followed
the case II transport mechanism. Case II transport mechanism suggests that the domi-
nant mechanism for drug transport is due to polymer relaxation as the gels swells. On
the other hand, formulations F2 and F3 followed the super Case II transport mechanism,
which is characterized by acceleration in solvent penetration into the polymer matrix.
The speed of solvent diffusion in the matrix is much greater than the swelling, with this
being the determining factor in the drug release (15).
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Zero order First order Higuchi Korsmeyer-Peppas
F1 0.9869 0.7231 0.9381 0.9815 1.03
F2 0.9909 0.7651 0.8925 0.9895 1.17
F3 0.9945 0.8004 0.9129 0.9798 1.25
F4 0.9926 0.6811 0.9441 0.9677 0.77
F5 0.9989 0.7371 0.9251 0.9847 0.97
F6 0.9053 0.5604 0.9724 0.9668 0.84
F7 0.8855 0.9819 0.8842 0.9961 0.39
F8 0.7814 0.4066 0.9697 0.9764 0.51
F9 0.9932 0.6602 0.9426 0.9988 0.73
CONCLUSIONS
In order to get more insight into the suitability of chitosan as a carrier for the stom-
ach specific drug delivery system, we have made an attempt to study the feasibility of
low molecular weight chitosan alone or in combination with another biocompatible
polymer, xanthan gum. The prepared hydrodynamically balanced capsule formulations
exhibited excellent in vitro buoyancy and were capable of sustaining the release of model
drug CP. Considering the experimental data, it may be concluded that LMCH alone, or
in combination with XG, is a potential polymeric carrier suitable for the development of
a hydrodynamically balanced system for the stomach specific delivery of drugs with an
absorption window in the upper GIT.
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S A @ E T A K
Kitozan male molekulske mase kao nosa~ hidrodinami~ki uravnote`enog
sustava za usporenu isporuku ciprofloksacin hidroklorida
ANURAG VERMA, ASHOK K. BANSAL, AMITAVA GHOSH i JAYANTA K. PANDIT
Zbog svoje biokompatibilnosti, biorazgradljivosti i netoksi~nosti kitozan je vrlo in-
teresantan istra`iva~ima u podru~ju farmaceutske tehnologije. Najvi{e se upotrebljavao
u dizajniranju razli~itih sustava za isporuku lijekova ali vrlo malo za sustave za specifi-
~nu isporuku u `elucu. Cilj ovog rada bio je ispitati mogu}nost upotrebe kitozana male
molekulske mase (LMCH) kao nosa~a u hidrodinami~ki balansiranom sustavu (HBS) za
usporenu isporuku vodotopljivog lijeka ciprofloksacin hidroklorida (CP). Pripravljene su
razli~ite formulacije stvaranjem fizi~ke smjese lijeka i polimera u razli~itim omjerima, koje
su potom kapsulirane u `elatinske kapsule. Svi su pripravci za vrijeme cijelog ekspe-
rimenta ostali plutati u 0,01mol L 1 HCl (pH 1,2). Ispitivan je i u~inak ksantan gume
(XG) ili etilceluloze (EC) na osloba|anje lijeka. Osloba|anje lijeka nultog reda postignuto
je iz formulacija koje sadr`e samo LMCH ili LMCH u kombinaciji sa XG i u jednom slu-
~aju s EC. Dobiveni rezultati pokazuju da je LMCH, sam ili u kombinaciji sa XG, izvrstan
materijal za sustave za specifi~nu isporuku CP iz hidrodinami~ki balansiranih kapsula.
Klju~ne rije~i: kitozan male molekulske mase, ksantan guma, ciprofloksacin, hidrodinami~ki urav-
note`ene kapsule, osloba|anje u `elucu
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